Skip to navigation

A Pipeline of Precision Therapeutics

Mirati is developing a rich pipeline of drug candidates targeting genetic and epigenetic drivers of cancer. Each program is based on a scientific rationale to identify and treat patients most likely to respond to Mirati’s targeted therapies. This includes the use of companion diagnostic assays that detect mutations of specific cancer genes.

Glesatinib (MGCD265)
Sitravatinib (MGCD516)
Mocetinostat (MGCD103)

Genetically Selected Populations in NSCLC*
Improving Checkpoint Inhibitors in NSCLC
Scientifically Based Expansion Opportunities
Glesatinib
(MGCD265)
Phase 2 Selected MET/Axl Alterations
Phase 2 Combination with PD-1
Phase 1b MET & Axl in EGFR Resistance in combination with T790M in NSCLC
Sitravatinib
(MGCD516)
Phase 2 Selected RET, CHR4q12, CBL, Trk, DDR Alterations
Phase 2 Combination with PD-1
Phase 1b Profile in combination with PD-1 in solid tumors
image
Image: Trifold Pipeline Chart